A prospective, international, multicenter, open-label, randomized, comparative study of efficacy and safety of Relipoietin (Reliance Life Sciences Pvt. Ltd., India) and of medicinal drug EprexÂ® (Cilag AG, Switzerland) in the treatment of anemia in patients with chronic kidney disease on hemodialysis - Nil

Start Date10 Feb 2013

Sponsor / Collaborator-

EUCTR2006-004929-28-LT / Not yet recruitingNot Applicable

Prospective, Multicentre, Randomised, Double-Blind, Parallel Group Study Comparing the Therapeutic Biosimilarity of Epostim (GMX) with Eprex (J&J) when given Intravenously to Patients undergoing Chronic Haemodialysis and on Maintenance Erythropoietin Treatment for Anaemia Associated with End-Stage Renal Disease (ESRD)

Start Date01 Oct 2008

Sponsor / Collaborator-

100 Clinical Results associated with Epoetin alfa biosimilar(Reliance GeneMedix Ltd.)

100 Translational Medicine associated with Epoetin alfa biosimilar(Reliance GeneMedix Ltd.)

100 Patents (Medical) associated with Epoetin alfa biosimilar(Reliance GeneMedix Ltd.)

Literatures (Medical) associated with Epoetin alfa biosimilar(Reliance GeneMedix Ltd.)

01 Jul 2019·Bulletin of Experimental Biology and MedicineQ4 · MEDICINE

Combined Effect of Bone Morphogenetic Protein-2 and Erythropoietin on Regeneration of Cranial Bone Defects in Mice

Q4 · MEDICINE

Article

Author: Strukova, N V ; Orlova, P A ; Nikitin, K E ; Manskikh, V N ; Gintsburg, A L ; Bartov, M S ; Lunin, V G ; Gromov, A V ; Krivozubov, M S ; Manukhina, M S ; Karyagina, A S ; Grunina, T M

Using mouse model of regeneration of critical size cranial defects, we studied combined effect of 1 and 10 μg of BMP-2 of prokaryotic origin and recombinant erythropoietin (Epostim) injected subcutaneously in the area of bone defect in a total dose of 6000 U/kg. Erythropoietin considerably improved quantitative and qualitative characteristics of the bone tissue in the site of implantation when used in combination with BMP-2 in both concentrations.

01 Jan 2019·Biochemistry (Moscow)Q4 · BIOLOGY

Recombinant Human Erythropoietin Proteins Synthesized in Escherichia coli Cells: Effects of Additional Domains on the in vitro and in vivo Activities

Q4 · BIOLOGY

Article

Author: Voronina, E V ; Cherepushkin, S A ; Manskikh, V N ; Nikitin, K E ; Grunina, T M ; Lyaschuk, A M ; Boksha, I S ; Generalova, M S ; Orlova, P A ; Trusova, I N ; Karyagina, A S ; Poponova, M S ; Gromov, A V ; Soboleva, L A ; Grishin, A V ; Marigin, R A ; Strukova, N V

The aim of this work was to compare biological activities of three variants of bacterially expressed human recombinant erythropoietin (EPO) with additional protein domains: 6His-s-tag-EPO protein carrying the s-tag (15-a.a. oligopeptide from bovine pancreatic ribonuclease A) at the N-terminus and HBD-EPO and EPO-HBD proteins containing heparin-binding protein domains (HBD) of the bone morphogenetic protein 2 from Danio rerio at the N- and C-termini, respectively. The commercial preparation Epostim (LLC Pharmapark, Russia) produced by synthesis in Chinese hamster ovary cells was used for comparison. The EPO variant with the C-terminal HBD domain connected by a rigid linker (EPO-HBD) possesses the best properties as compared to HBD-EPO with the reverse domain arrangement. It was ~13 times more active in vitro (i.e., promoted proliferation of human erythroleukemia TF-1 cells) and demonstrated a higher rate of association with the erythropoietin receptor. EPO-HBD also exhibited the greatest binding to the demineralized bone matrix (DBM) and more prolonged release from the DBM among the four proteins studied. Subcutaneous administration of EPO-HBD immobilized on DBM resulted in significantly more pronounced vascularization of surrounding tissues in comparison with the other proteins and DBM alone. Therefore, EPO-HBD displayed better performance with regard to all the investigated parameters than other examined EPO variants, and it seems promising to study the possibility of its medical use.

100 Deals associated with Epoetin alfa biosimilar(Reliance GeneMedix Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B03XA01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia	-	Reliance GeneMedix Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis